CG Oncology, Inc. Common stock

NASDAQ:CGON

Biotechnology

Healthcare
$80.00 +2.23%

+$1.35 today

Market cap
$7.15B
Beta
0.31
P/E (TTM)
-28.0
EPS (TTM)
-$2.21
52W Low $23.65High $75.50

Volume 1.79M

Average 1.08M

CGON Pre-Tax Margin

Income before tax as a percentage of revenue.

CG Oncology, Inc. Common stockNASDAQ: CGON

Pre-Tax Margin · Q3 FY2026 · quarter ended Sep 2026

Pre-tax margin narrows to -3546.8%

Pre-tax margin was -3546.8% in Q3 FY2026, down 917.3 pp from a year earlier. On a trailing-twelve-month basis it was -3851.1%, up 3116.9 pp year over year. Over 3 fiscal years it widened by 14571.5 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-3546.8%+3286.0 pp QoQ
Last fiscal yearDec 2025
-3985.0%+3744.5 pp YoY
LTMSep 2026
-3851.1%+3116.9 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-917.3 pp——
1 year+3744.5 pp——
3 years+14571.5 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-3985.0%
Year-over-year change
+3744.5pp

Pre-Tax Margin vs competitors

How CGON compares with its peers on the latest reported figures

  • CGON's LTM Sep 2026 pre-tax margin of -3851.1% is the lowest of the 3 companies compared; the peer median is -353.2%.
  • Its year-over-year change of +3116.9 pp is the highest of 3, against a peer median of -68.4 pp.
  • Over three fiscal years its change of +14571.5 pp compares with a peer median of +86793.5 pp.
CGON Competitors Peer median
Pre-Tax Margin for CGON and competitors
Company Period LTM level YoY 3-year change
URGNUroGen Pharma Ltd.LTM Mar 2026-98.4% +48.8 pp+28.1 pp
IBRXImmunityBio, Inc.LTM Sep 2026-607.9% -185.5 pp+173558.8 pp
CGONCG Oncology, Inc. Common stockLTM Sep 2026-3851.1% +3116.9 pp+14571.5 pp
Peer median (excluding CGON) -353.2%-68.4 pp+86793.5 pp

Competitors are the stored peer set for CGON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.36M191K204K1.14M4.04M
Cost of Revenue10K15K45.75M82.1M4.65M
Gross Profit10.35M176K(45.55M)(80.96M)(607K)
Gross Margin99.9%92.1%-22327.5%-7108.3%-15.0%
Research & Development18.32M29.03M45.75M82.1M116.64M
Selling, General & Admin4.64M6.39M9.9M33.7M73.53M
Operating Expenses22.95M35.42M9.9M33.7M190.17M
Depreciation & Amortization10K15K17K32K1.45M
EBITDA(12.38M)(35.43M)(48.59M)(88.01M)(159.55M)
EBITDA Margin-119.5%-18548.2%-23818.6%-7726.7%-3949.3%
Operating Income(12.61M)(35.25M)(55.45M)(114.67M)(190.77M)
Operating Margin-121.7%-18453.4%-27180.9%-10067.3%-4722.1%
Interest Income006.9M26.62M29.93M
Interest Expense451K1K000
Other Income / Expenses(233K)(197K)6.84M26.63M29.78M
Income Before Tax(12.84M)(35.44M)(48.61M)(88.04M)(161M)
Pre-Tax Margin-124.0%-18556.5%-23827.0%-7729.5%-3985.0%
Income Tax Expense00000
Net Income(12.84M)(35.44M)(48.61M)(88.04M)(161M)
Net Margin-124.0%-18556.5%-23827.0%-7729.5%-3985.0%
EPS (Basic)(0.28)(0.66)(1.02)(1.41)(2.08)
EPS (Diluted)(0.28)(0.66)(1.02)(1.41)(2.08)
Weighted Avg Shares66.64M66.64M66.64M62.5M77.3M
Weighted Avg Shares (Diluted)66.64M66.64M66.64M62.5M77.3M

CG Oncology, Inc. Common stock

NASDAQ:CGON

Intrinsic Alpha fair value

Locked

Current Price

$80.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.